Seeking Alpha

EPS100Momentum's  Instablog

EPS100Momentum
Send Message
Author has a degree in Engineering and is an avid investor in the market. Experience in industrial materials and structures. In college studied atomic & nuclear physics as well as material engineering. Eastern European
My blog:
EPS100Momentum's Instablog at SeekingAlpha
  • Prostate Cancer cases could be rising further with men holding cell phones in pockets, they need a clinical trial for this asap. 0 comments
    Nov 16, 2010 12:30 PM | about stocks: DNDN, EDAP
    I am one of those men that love to keep cell phones in my pants pockets. Although no studies that I know of have been done on men that keep cell phones in their pockets vs. those that don't for prostate cancer. I believe this is one study that needs to be done asap.
    Cell Phone use and Cancer article

    November 16, 2010 07:16 AM Eastern Time 
    Research and Markets: Prostate Cancer Drug Futures 2010 - the Market is Set to Change with the Arrival of New Therapies That Will Prolong a Patient's Survival
     

    DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8f38a8/prostate_cancer_dr) has announced the addition of the "Prostate Cancer Drug Futures 2010" report to their offering.

    The prostate cancer (PC) market is on the verge of considerable change with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries

    The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.

    NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER:

    This all new web service, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

    WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:

    • Track the drugs progress and stay abreast of developments
    • Understand the drugs novelty and mode of action
    • Evaluate the strength of the company developing/producing the drug
    • Review opportunities and challenges with Espicoms unique 5-point competitive assessment
    • Know the launch timeframe for new products or indications
    • Be aware of promising mid-stage development candidates
    • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
    • Review significant clinical trial results

    STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS:

    For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:

    • Novelty/rationale for mechanism of action
    • Current status
    • Proof of concept/clinical data
    • Development risks
    • Company expertise
    • Competition within the market-place
    • Sales forecast (for key late-stage and launched products)
    • Competitor ratio analysis score
    • Clinical trial results

    OVER 45 PROSTATE DRUGS COVERED IN THIS REPORT, SOME INCLUDE:

    • Approved
    • Bicalutamide
    • Cabazitaxel
    • Degarelix
    • Docetaxel
    • Mitoxantrone
    • Paclitaxel
    • Sipuleucel-T
    • Filed
    • Dutasteride
    • Phase III
    • Abiraterone acetate
    • Bortezomib
    • Cixutumumab
    • E75 GM-CSF adjuvant vaccine
    • Enzastaurin
    • Figitumumab
    • Ixabepilone
    • Sagopilone
    • Vadimezan

    To view all drugs covered in this report and for more information visit http://www.researchandmarkets.com/research/8f38a8/prostate_cancer_dr

    Source: Espicom Business Intelligence Ltd

    Stocks: DNDN, EDAP
Back To EPS100Momentum's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.